Physician profile
Ingrid Brown
NPI 1700917580
$1,316.24
in general payments reported to CMS, 2019-2025
20 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $119 · 2021: $155 · 2022: $339 · 2023: $248 · 2024: $33.43 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $552.55 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $255.63 | 2022-2023 | |
| Astellas Pharma US INC | $137.75 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $97.25 | 2019-2025 | Novasure, Myosure Tissue Removal Device |
| Avion Pharmaceuticals | $44.84 | 2019-2023 | Balcoltra |
| Lupin INC. | $28.92 | 2019 | |
| Organon LLC | $24.87 | 2022 | |
| Sumitomo Pharma America, INC. | $19.62 | 2023 | Myfembree |
| Millicent US INC | $19.42 | 2025 | Femlyv |
| Exeltis, USA INC. | $16.67 | 2019 | |
| Allergan, INC. | $16.38 | 2019 | |
| Currax Pharmaceuticals LLC | $16.12 | 2022 | |
| Biogen, INC. | $15.98 | 2024 | Zurzuvae |
| Shield Therapeutics INC | $15.69 | 2023 | Accrufer |
| Therapeuticsmd, INC. | $14.66 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $14.51 | 2021 | |
| Ascend Therapeutics US, LLC | $13.20 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.18 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.